Home Featured Page 112

Featured

Latest

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Optimi Health To Supply MDMA For Therapist Experiential Training Program at...

Psychedelic Bulletin #139: Kentucky Earmarks $42m for Ibogaine Studies; Reunion Announces...

Numinus Appoints New Chief Financial Officer

PT415 – Psychedelic Science 2023: The Largest Psychedelic Conference in History

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

PharmaTher Holdings Provides Corporate Update

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Wesana Health Announces Voting Results of AGSM

PT414 – Lena Franklin & Jeff Glattstein – The EAST Institute:...

Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by...

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Optimi Health To Supply MDMA For Therapist Experiential Training Program at...

Psychedelic Bulletin #139: Kentucky Earmarks $42m for Ibogaine Studies; Reunion Announces...

Numinus Appoints New Chief Financial Officer

PT415 – Psychedelic Science 2023: The Largest Psychedelic Conference in History

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

PharmaTher Holdings Provides Corporate Update

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Wesana Health Announces Voting Results of AGSM

PT414 – Lena Franklin & Jeff Glattstein – The EAST Institute:...

Apex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by...

EDITOR PICKS

Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for...

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY